ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1438

Performance of Combined MRI SI Joint Active and Structural Lesions in Diagnosing Axial SpA: A Prospective Cohort Study

Liese de Bruin1, Mary Lucy Marques2, Miranda van Lunteren3, Manouk de hOoge4, Sofia Exarchou5, Karen Minde Fagerli6, Roberta Ramonda7, Robert Landewé8, Floris van Gaalen9, Desiree van der Heijde10 and Sofia Ramiro11, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center, Coimbra, Zuid-Holland, Portugal, 3Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, 4Dept. of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, 5Lund University, Åkarp, Sweden, 6Diakonhjemmet Hospital, Oslo, Norway, 7Rheumatology Unit, University of Padova, Italy, Padova, Italy, 8Amsterdam University Medical Center, Meerssen, Netherlands, 9LUMC, Leiden, Zuid-Holland, Netherlands, 10Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 11Leiden University Medical Center, Bunde, Netherlands

Meeting: ACR Convergence 2024

Keywords: Diagnostic criteria, Imaging, Magnetic resonance imaging (MRI), spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 17, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Definitions for active and structural lesions on MRI of the SI joints (MRI-SIJ) typical of axial SpA (axSpA), proposed by de Hooge and the ASAS MRI study group, were assessed for their predictive validity.(de Bruin et al. 2024) However, the MRI study group active lesions definition has not been compared with the current ASAS definition for positive MRI-SIJ (ASAS-MRI-SIJ+), nor combinations of active lesions and structural lesions have been assessed. We aimed to compare the proposed MRI study group definition for active lesions with that of ASAS-MRI-SIJ+ and evaluate the predictive validity of different combinations of active lesions and structural lesions.

Methods: Patients with chronic back pain (≥3 months; ≤2 years; onset < 45 years) from the SPondyloArthritis Caught Early (SPACE) inception cohort had a two-year follow-up at which they were diagnosed by a rheumatologist as axSpA or no-axSpA. Patients with a ‘definite’ (level of confidence about the diagnosis ≥7) or ‘most likely’ (level of confidence < 7 and a consistent diagnosis in the last 2 visits) diagnosis were included in this analysis. Three central readers assessed baseline MRI-SIJ for bone marrow edema, erosions, and fat lesions. MRI-SIJ data that were available for ≥2 readers were analyzed for the consensus between ≥2 readers on scored lesions. Different combinations of active lesions and/or structural lesions were created based on the component definitions of de Hooge, MRI study group and ASAS-MRI-SIJ+ (Table 1). Sensitivity, specificity, positive and negative predictive values (PPV and NPV) were calculated for each combination. Definitions with a specificity ≥95% and PPV ≥95% were accepted.

Results: In total, we analyzed 643 patients (age 30 (SD 8) years; 39% males; 52% axSpA). Active lesions as defined by the ASAS-MRI-SIJ+ performed best by having higher sensitivity (40% vs 31%) with similar specificity compared to the active lesions of the MRI study group (98% vs 99%) (Table 1). All combinations of active lesions and structural lesions by de Hooge met the threshold, while the structural lesions of the MRI study group met the threshold only in presence of active lesions. Structural lesions alone (i.e. without active lesions) contributed with only a small gain in sensitivity, between 6-11% (Figure 1).

Conclusion: The current ASAS-MRI-SIJ+ definition performs better than the new MRI study group active lesions proposal. Structural lesions have only a small gain in sensitivity for identifying axSpA in this group of patients with short symptom duration. In combining active lesions and structural lesions, ASAS-MRI-SIJ+ and de Hooge structural lesions have the best performance.

Supporting image 1

Supporting image 2

Figure 1. Added value of structural lesions, compared to active lesions, as measured with sensitivity to identify patients with axSpA (n=643). Details of the individual definitions are further explained in Table 1.


Disclosures: L. de Bruin: None; M. Marques: None; M. van Lunteren: None; M. de hOoge: None; S. Exarchou: AbbVie/Abbott, 1, Eli Lilly, 1, Janssen, 1, Novartis, 1, UCB, 1; K. Minde Fagerli: None; R. Ramonda: AbbVie/Abbott, 6, Eli Lilly, 2, 6, Novartis, 1, 6, Pfizer, 6, UCB, 6; R. Landewé: AbbVie/Abbott, 2, Eli Lilly, 2, Galapagos, 2, Janssen, 2, Novartis, 2, Pfizer, 2, UCB, 2; F. van Gaalen: AbbVie, 12, Personal fees, BMS, 12, Personal fees, Eli Lilly, 12, Personal fees, Jacobus Stichting, 5, MSD, 12, Personal fees, Novartis, 2, 5, Stichting ASAS, 5, Stichting Vrienden van Sole Mio, 5, UCB Pharma, 5; D. van der Heijde: AbbVie, 2, ArgenX, 2, BMS, 2, Eli Lilly, 2, Galapagos, 2, GSK, 2, Imaging Rheumatology BV, 3, Janssen, 2, Novartis, 2, Pfizer, 2, Takeda, 2, UCB Pharma, 2; S. Ramiro: AbbVie, 1, 2, 5, 6, Alfasigma, 1, 2, 5, Galapagos, 1, 2, 5, Lilly, 1, 2, 6, MSD, 2, 5, 6, Novartis, 1, 2, 5, 6, Pfizer, 1, 2, 5, 6, UCB, 1, 2, 5, 6.

To cite this abstract in AMA style:

de Bruin L, Marques M, van Lunteren M, de hOoge M, Exarchou S, Minde Fagerli K, Ramonda R, Landewé R, van Gaalen F, van der Heijde D, Ramiro S. Performance of Combined MRI SI Joint Active and Structural Lesions in Diagnosing Axial SpA: A Prospective Cohort Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/performance-of-combined-mri-si-joint-active-and-structural-lesions-in-diagnosing-axial-spa-a-prospective-cohort-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-combined-mri-si-joint-active-and-structural-lesions-in-diagnosing-axial-spa-a-prospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology